Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations
- PMID: 12200392
- DOI: 10.1182/blood-2002-02-0584
Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations
Abstract
Aceruloplasminemia is a recessive disorder characterized by anemia, iron overload, and neurodegeneration, caused by the absence of ceruloplasmin (Cp), a multicopper oxidase important for iron export. Few patients homozygous for loss of function mutations of the Cp gene have been reported. We describe a 62-year-old white woman with heavy liver iron overload, diabetes, anemia, and neurologic symptoms. She was compound heterozygote for 2 novel mutations that result in the absence of hepatocyte Cp: an adenine insertion at nucleotide 2917 causing a truncated protein and a C-G transversion causing a glutamine-->glutamic acid substitution at position 146. Although rare in whites, aceruloplasminemia should be considered in the differential diagnosis of unexplained anemia associated with iron overload, because these features anticipate progressive neurologic symptoms. We propose that anemia, secondary to the impaired macrophage iron release, plays a major role in hepatic iron overload through increased absorption mediated by the erythroid regulator.
Similar articles
-
Identification and in silico characterization of a novel compound heterozygosity associated with hereditary aceruloplasminemia.Scand J Gastroenterol. 2007 Sep;42(9):1088-94. doi: 10.1080/00365520701278810. Scand J Gastroenterol. 2007. PMID: 17710675
-
Novel ceruloplasmin mutation causing aceruloplasminemia with hepatic iron overload and diabetes without neurological symptoms.Clin Genet. 2014 Mar;85(3):300-1. doi: 10.1111/cge.12145. Epub 2013 Apr 5. Clin Genet. 2014. PMID: 23557349 No abstract available.
-
[Aceruloplasminemia, a rare condition not to be overlooked].Rev Med Interne. 2020 Nov;41(11):769-775. doi: 10.1016/j.revmed.2020.06.002. Epub 2020 Jul 16. Rev Med Interne. 2020. PMID: 32682623 Review. French.
-
Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights.J Hepatol. 2002 Jun;36(6):851-6. doi: 10.1016/s0168-8278(02)00042-9. J Hepatol. 2002. PMID: 12044538
-
Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis.Ann N Y Acad Sci. 2004 Mar;1012:299-305. doi: 10.1196/annals.1306.024. Ann N Y Acad Sci. 2004. PMID: 15105274 Review.
Cited by
-
Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms.Neurochem Res. 2007 Oct;32(10):1646-54. doi: 10.1007/s11064-007-9346-5. Epub 2007 Apr 28. Neurochem Res. 2007. PMID: 17468954 Review.
-
T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation.Neurology. 2008 Apr 29;70(18):1614-9. doi: 10.1212/01.wnl.0000310985.40011.d6. Neurology. 2008. PMID: 18443312 Free PMC article.
-
Disturbance of iron metabolism in Parkinson's disease -- ultrasonography as a biomarker.Neurotox Res. 2006 Jan;9(1):1-13. doi: 10.1007/BF03033302. Neurotox Res. 2006. PMID: 16464747 Review.
-
Aceruloplasminemia: Waiting for an Efficient Therapy.Front Neurosci. 2018 Dec 4;12:903. doi: 10.3389/fnins.2018.00903. eCollection 2018. Front Neurosci. 2018. PMID: 30568573 Free PMC article.
-
Aceruloplasminemia: a case report.Intern Emerg Med. 2008 Dec;3(4):395-9. doi: 10.1007/s11739-008-0150-2. Epub 2008 Apr 12. Intern Emerg Med. 2008. PMID: 18408989 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous